Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

BeOne Medicines' Beqalzi (sonrotoclax) receives FDA accelerated approval for relapsed or refractory mantle cell lymphoma as first BCL-2 inhibitor
Small molecule, cancer, BCL-2 inhibitor, mantle cell lymphoma, relapsed or refractory, BTK inhibitor - Read more

Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax gains FDA approval for newly diagnosed acute myeloid leukemia
Small molecule, cancer, combination therapy, acute myeloid leukemia, BCL-2 inhibitor, hypomethylating agent - Read more

AstraZeneca, Owkin ink three-year agentic AI licensing deal for research and competitive intelligence automation
Licensing deal, AI/ML, drug discovery, R&D, data analytics - Read more

Fosun Pharma pays $60M for option on AriBio's phase 3 Alzheimer's asset AR1001, with $80M option fee
Licensing deal, neurological, small molecule, milestone payments - Read more

Cantex Pharmaceuticals, Headlamp Health partner to identify MS responders for azeliragon using agentic AI
Research collaboration, neurological, AI/ML, small molecule, drug discovery - Read more

Fangzhou, Tenry Pharmaceutical partner to advance AI-powered chronic disease management via GLP-1 therapy platform
Strategic partnership, AI/ML, chronic disease, digital health, small molecule, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Novo Nordisk's oral semaglutide delivers up to 21.6% weight loss in Ph3 obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, oral semaglutide - Read more

Encoded Therapeutics' ETX101 shows durable seizure reduction in Ph1/2 for SCN1A-positive Dravet syndrome
Gene therapy, neurological, AAV gene therapy, Dravet syndrome, SCN1A, epilepsy - Read more

Shanghai Yiminokang Biotechnology raises 250M yuan ($36.78M) Series A for antibody discovery platforms
Antibody discovery, AI/ML platform, CRISPR, gene editing, platform technology - Read more

QuartzBio receives undisclosed growth investment from Eir Partners for platform expansion
Software platform, biomarker discovery, AI-driven, clinical-stage, data analytics - Read more

SwishX raises $2.2M seed funding for agentic AI platform serving pharma operations
AI/ML platform, software platform, pharmaceutical, medtech, services - Read more

Autoimmunity BioSolutions raises $1M Seed Extension, advancing personalized genetically-guided immuno-corrective therapy
Autoimmune, personalized medicine, genetic medicine, preclinical - Read more

Avant Genomics raises $3M+ in funding for automated liquid biopsy cancer detection platform
Oncology, liquid biopsy, automation, precision diagnostics - Read more

Icon opens early-phase Clinical Research Unit in San Antonio, adds satellite clinics in Houston and Lawrence
CRO services, operational, strategic, infrastructure expansion - Read more

Vetter breaks ground on new Saarlouis production site, investing €500M ($586.75M) to create up to 2,000 jobs
Injectable drugs, CDMO, operational, major transaction - Read more

Galapagos rebrands as Lakefront Biotherapeutics after strategic overhaul, CEO change, and cell therapy exit
Cell therapy, oncology, strategic, rebranding, major transaction - Read more

Zydus to acquire Assertio Holdings for $23.50 per share, totaling ~$166.4M
Small molecule, specialty pharma, strategic, major transaction - Read more

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease gene therapy development at ASGCT
Gene therapy, rare disease, neurological, AI-driven drug discovery - Read more

MHRA opens Northern Ireland hub to boost life sciences collaboration and regulatory support for region's 250 businesses
Life sciences, regulatory, strategic, operational - Read more

Merck KGaA eyes M&A expansion to strengthen its "rather slim" early-stage pharma pipeline
Small molecule, oncology, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Valneva cuts up to 15% of workforce amid declining travel vaccine demand and geopolitical headwinds
Vaccine, infectious disease, cost reduction, operational - Read more

Medtronic shuts Santa Rosa stent plant, restructures cardiovascular unit amid activist investor pressure
Medical device, cardiovascular, strategic, operational, cost reduction - Read more

Humacyte cuts 25% of workforce, slashes $14.3M in spending amid sluggish Symvess artery implant sales
Bioengineered implant, vascular, cost reduction, operational - Read more

Takeda axes TAK-004, marking fourth nausea and vomiting pipeline failure amid strategic shift
Peptide agonist, gastrointestinal, strategic, pipeline - Read more

Takeda expands restructuring, cutting 4,500 roles to save $1.3B annually by fiscal 2028
Operational, cost reduction, strategic, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here